tetano
Editor, Senior Moderator
JAMA Netw Open
. 2023 Oct 2;6(10):e2336854.
doi: 10.1001/jamanetworkopen.2023.36854. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19
Alberto Mateo-Urdiales[SUP] 1 [/SUP], Chiara Sacco[SUP] 1 2 [/SUP], Daniele Petrone[SUP] 1 [/SUP], Antonino Bella[SUP] 1 [/SUP], Flavia Riccardo[SUP] 1 [/SUP], Martina Del Manso[SUP] 1 [/SUP], Marco Bressi[SUP] 1 [/SUP], Andrea Siddu[SUP] 3 [/SUP], Silvio Brusaferro[SUP] 4 [/SUP], Anna Teresa Palamara[SUP] 1 [/SUP], Giovanni Rezza[SUP] 3 [/SUP], Patrizio Pezzotti[SUP] 1 [/SUP], Massimo Fabiani[SUP] 1 [/SUP]; Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry
Collaborators, Affiliations
Importance: Protein recombinant vaccine NVX-CoV2373 (Novavax) against COVID-19 was authorized for its use in adults in late 2021, but evidence on its estimated effectiveness in a general population is lacking.
Objective: To estimate vaccine effectiveness of a primary cycle with NVX-CoV2373 against SARS-CoV-2 infection and symptomatic COVID-19.
Design, setting, and participants: Retrospective cohort study linking data from the national vaccination registry and the COVID-19 surveillance system in Italy during a period of Omicron predominance. All adults starting a primary vaccination with NVX-CoV2373 between February 28 and September 4, 2022, were included, with follow-up ending on September 25, 2022. Data were analyzed in February 2023.
Exposures: Partial (1 dose only) vaccination and full vaccination (2 doses) with NVX-CoV-2373.
Main outcomes and measures: Notified SARS-CoV-2 infection and symptomatic COVID-19. Poisson regression models were used to estimate effectiveness against both outcomes. Adjusted estimated vaccine effectiveness was calculated as (1 - incidence rate ratio) × 100.
Results: The study included 20 903 individuals who started the primary cycle during the study period. Median (IQR) age of participants was 52 (39-61) years, 10 794 (51.6%) were female, and 20 592 participants (98.5%) had no factors associated with risk for severe COVID-19. Adjusted estimated vaccine effectiveness against notified SARS-CoV-2 infection in those partially vaccinated with NVX-CoV2373 was 23% (95% CI, 13%-33%) and was 31% (95% CI, 22%-39%) in those fully vaccinated. Estimated vaccine effectiveness against symptomatic COVID-19 was 31% (95% CI, 16%-44%) in those partially vaccinated and 50% (95% CI, 40%-58%) in those fully vaccinated. Estimated effectiveness during the first 4 months after completion of the primary cycle decreased against SARS-CoV-2 infection but remained stable against symptomatic COVID-19.
Conclusions and relevance: This cohort study found that, in an Omicron-dominant period, protein recombinant vaccine NVX-CoV2373 was associated with protection against SARS-CoV-2 infection and symptomatic COVID-19. The use of this vaccine could remain an important element in reducing the impact of the SARS-CoV-2 pandemic.
. 2023 Oct 2;6(10):e2336854.
doi: 10.1001/jamanetworkopen.2023.36854. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19
Alberto Mateo-Urdiales[SUP] 1 [/SUP], Chiara Sacco[SUP] 1 2 [/SUP], Daniele Petrone[SUP] 1 [/SUP], Antonino Bella[SUP] 1 [/SUP], Flavia Riccardo[SUP] 1 [/SUP], Martina Del Manso[SUP] 1 [/SUP], Marco Bressi[SUP] 1 [/SUP], Andrea Siddu[SUP] 3 [/SUP], Silvio Brusaferro[SUP] 4 [/SUP], Anna Teresa Palamara[SUP] 1 [/SUP], Giovanni Rezza[SUP] 3 [/SUP], Patrizio Pezzotti[SUP] 1 [/SUP], Massimo Fabiani[SUP] 1 [/SUP]; Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry
Collaborators, Affiliations
- PMID: 37792377
- DOI: 10.1001/jamanetworkopen.2023.36854
Importance: Protein recombinant vaccine NVX-CoV2373 (Novavax) against COVID-19 was authorized for its use in adults in late 2021, but evidence on its estimated effectiveness in a general population is lacking.
Objective: To estimate vaccine effectiveness of a primary cycle with NVX-CoV2373 against SARS-CoV-2 infection and symptomatic COVID-19.
Design, setting, and participants: Retrospective cohort study linking data from the national vaccination registry and the COVID-19 surveillance system in Italy during a period of Omicron predominance. All adults starting a primary vaccination with NVX-CoV2373 between February 28 and September 4, 2022, were included, with follow-up ending on September 25, 2022. Data were analyzed in February 2023.
Exposures: Partial (1 dose only) vaccination and full vaccination (2 doses) with NVX-CoV-2373.
Main outcomes and measures: Notified SARS-CoV-2 infection and symptomatic COVID-19. Poisson regression models were used to estimate effectiveness against both outcomes. Adjusted estimated vaccine effectiveness was calculated as (1 - incidence rate ratio) × 100.
Results: The study included 20 903 individuals who started the primary cycle during the study period. Median (IQR) age of participants was 52 (39-61) years, 10 794 (51.6%) were female, and 20 592 participants (98.5%) had no factors associated with risk for severe COVID-19. Adjusted estimated vaccine effectiveness against notified SARS-CoV-2 infection in those partially vaccinated with NVX-CoV2373 was 23% (95% CI, 13%-33%) and was 31% (95% CI, 22%-39%) in those fully vaccinated. Estimated vaccine effectiveness against symptomatic COVID-19 was 31% (95% CI, 16%-44%) in those partially vaccinated and 50% (95% CI, 40%-58%) in those fully vaccinated. Estimated effectiveness during the first 4 months after completion of the primary cycle decreased against SARS-CoV-2 infection but remained stable against symptomatic COVID-19.
Conclusions and relevance: This cohort study found that, in an Omicron-dominant period, protein recombinant vaccine NVX-CoV2373 was associated with protection against SARS-CoV-2 infection and symptomatic COVID-19. The use of this vaccine could remain an important element in reducing the impact of the SARS-CoV-2 pandemic.